Modafinil: An antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers

Biological Psychiatry

Volumn 42, Issue 12, 1997, Pages 1181-1183

  Ferraro, Luca ^a   Antonelli, Tiziana ^a   O'Connor, William T ^b   Tanganelli, Sergio ^c   Rambert, Francis A ^d   Fuxe, Kjell ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d Neuropsychopharmacologie   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

D amphetamine; Dopamine; Gamma aminobutyric acid; Modafinil; Release; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID; DEXAMPHETAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; MODAFINIL; NOMIFENSINE; VANOXERINE;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG SCREENING; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; BIOGENIC AMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; GAMMA-AMINOBUTYRIC ACID; MALE; MICRODIALYSIS; NARCOLEPSY; NUCLEUS ACCUMBENS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031574307     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00353-3     Document Type: Article

References (9)

1. Bastuji H, Jouvet M (1988): Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12:695-700.
2. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K (1996a): The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220:5-8.
3. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K (1996b): The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 306:33-39.
4. Fuxe K, Rambert FA, Ferraro L, O'Connor WT, Laurent P, Agnati LF, (1996): Preclinical studies with modafinil. Evidence for vigilance enhancement and neuroprotection. Drugs Today 32:313-326.
5. Koob GF, Bloom FE (1988): Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
6. Morari M, O'Connor WT, Ungerstedt U, Fuxe K (1993): NMDA differently regulates extracellular dopamine, GABA and glutamate levels in the dorsolateral neostriatum of the halothane anaesthetized rat: An in vivo microdialysis study. J Neurochem 60:1884-1893.
7. Rambert FA, Pessonnier J, Duteil J (1990): Modafinil-, amphetamine- and methylphenidate-induced hyperactivities in mice involve different mechanisms. Eur J Pharmacol 183:455-456.
8. Santiago M, Westerink BHC (1992): The role of GABA receptors in the control of nigrostriatal dopaminergic neurons: Dual-probe microdialysis study in awake rats. Eur J Pharmacol 219:175-181.
9. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U (1987): A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401:322-330.